Delivery Order SPE2DB22D1103-SPE2DB24FTNV5

Award Date 7/19/24
Potential Completion Date 7/22/24
Potential Value $1.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The contract has a ceiling value of $71,009.21 and an ultimate completion date of February 10, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Restasis 0.05% eye emulsion, a specialty medication. The contract is a firm fixed-price delivery order with a ceiling value of $1,406.73 and a completion date of November 1, 2022. This contract is part of a larger Indefinite Delivery Contract (IDC) between...
This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $4,695.65, is for the delivery of Restasis 0.05% Eye Emulsion in 60-count packs. The contract has a firm fixed-price pricing type and an ultimate completion date of December 12, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Restasis 0.05% eye emulsion, a specialty medication, and has a firm fixed price ceiling value of $2,186.52. The contract has a completion date of March 1, 2023 and was awarded on February 28, 2023. This order is part of a larger Indefinite Delivery Contract (IDC) valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The contract has a ceiling value of $4,527.84 and an ultimate completion date of January 8, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Restasis 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has a ceiling value of $2,860.07 and a period of performance through May 8, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication. The contract has a ceiling value of $1,117.80 and a performance period extending through May 8, 2025. It is a firm fixed-price contract, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp's Corporate Office Division. The contract is for the supply of RESTASIS 0.05% Eye Emulsion 60s, a prescription pharmaceutical product, with a ceiling value of $3,126.34 and a completion date of May 24, 2024. AmerisourceBergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) with the DLA valued up to $999,999,999.00...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The contract has a ceiling value of $4,748.43 and a period of performance ending on September 4, 2024. It is a firm-fixed-price contract. This delivery order is issued under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at up...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of Restasis 0.05% eye emulsion, a prescription eye medication. The contract has a ceiling value of $3,477.35 and an ultimate completion date of May 13, 2022. The contract is a firm fixed-price delivery order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds...
  • SPE2DB22D1103
    Indefinite Delivery Contract
  • SPE2DB22D1103-SPE2DB24FTNV5
    Delivery Order

This is a delivery order contract awarded to Amerisourcebergen Drug Corp, Corporate Office Division, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the supply of the pharmaceutical product Restasis 0.05% eye emulsion, with a ceiling value of $1,529.98 and a completion date of July 22, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract has no set-aside designation.

Generated 10/18/24, 9:20 AM